Galectin Therapeutics Inc. (GALT) Director Purchases $12,950.00 in Stock
Galectin Therapeutics Inc. (NASDAQ:GALT) Director Marc Rubin bought 7,000 shares of Galectin Therapeutics stock in a transaction dated Friday, December 8th. The stock was acquired at an average cost of $1.85 per share, for a total transaction of $12,950.00. Following the completion of the transaction, the director now directly owns 55,581 shares in the company, valued at $102,824.85. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) traded up $0.42 on Monday, reaching $2.43. 4,246,100 shares of the company’s stock were exchanged, compared to its average volume of 430,631. Galectin Therapeutics Inc. has a twelve month low of $0.88 and a twelve month high of $3.68.
Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. equities research analysts anticipate that Galectin Therapeutics Inc. will post -0.52 earnings per share for the current year.
GALT has been the topic of a number of analyst reports. HC Wainwright upped their price target on shares of Galectin Therapeutics from $3.50 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, November 28th. Roth Capital initiated coverage on shares of Galectin Therapeutics in a research note on Thursday, October 19th. They set a “buy” rating and a $8.00 target price on the stock. Seaport Global Securities restated a “buy” rating and set a $5.00 target price on shares of Galectin Therapeutics in a research note on Friday, October 6th. Zacks Investment Research raised shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Thursday, November 30th. Finally, ValuEngine lowered shares of Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $4.55.
A number of institutional investors and hedge funds have recently made changes to their positions in GALT. Northern Trust Corp grew its holdings in Galectin Therapeutics by 4.4% during the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after buying an additional 3,176 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Galectin Therapeutics by 18.2% during the 2nd quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock valued at $2,144,000 after acquiring an additional 134,165 shares during the last quarter. Advisor Group Inc. boosted its position in shares of Galectin Therapeutics by 10.4% during the 2nd quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock valued at $1,191,000 after acquiring an additional 45,700 shares during the last quarter. Finally, Virtu KCG Holdings LLC boosted its position in shares of Galectin Therapeutics by 24.4% during the 2nd quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after acquiring an additional 21,008 shares during the last quarter. 11.07% of the stock is owned by institutional investors and hedge funds.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.